Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robbie G Majzner

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Nature Communications|April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Nature Cancer|July 11, 2022
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1Nathaniel W Mabe, Min Huang, Guillermo N Dalton, et al.
Nature Medicine|April 29, 2020
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumorsJohanna Theruvath, Elena Sotillo, Christopher W Mount, et al.
Nature|May 15, 2024
Engineered CD47 protects T cells for enhanced antitumour immunitySean A Yamada-Hunter, Johanna Theruvath, Brianna J McIntosh, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Cancer Cell|December 30, 2022
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasBrian J Sworder, David M Kurtz, Stefan K Alig, et al.
Nature|November 8, 2023
Latent human herpesvirus 6 is reactivated in CAR T cellsCaleb A Lareau, Yajie Yin, Katie Maurer, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Nature Communications|April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Nature Cancer|July 11, 2022
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1Nathaniel W Mabe, Min Huang, Guillermo N Dalton, et al.
Nature Medicine|April 29, 2020
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumorsJohanna Theruvath, Elena Sotillo, Christopher W Mount, et al.
Nature|May 15, 2024
Engineered CD47 protects T cells for enhanced antitumour immunitySean A Yamada-Hunter, Johanna Theruvath, Brianna J McIntosh, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Cancer Cell|December 30, 2022
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasBrian J Sworder, David M Kurtz, Stefan K Alig, et al.
Nature|November 8, 2023
Latent human herpesvirus 6 is reactivated in CAR T cellsCaleb A Lareau, Yajie Yin, Katie Maurer, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Pageof 6